Söndag 23 Februari | 23:13:07 Europe / Stockholm

Prenumeration

2025-02-19 07:20:00

Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and directed share issue in December-January. This will fund 2025 and the recruitment of 240 patients in the phase IIb study Advance.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/